[{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"463898f9-d0f2-4eeb-ad5a-ad7d4f465a1f","acronym":"ASC4MORE","url":"https://clinicaltrials.gov/study/NCT03578367","created_at":"2021-01-18T17:36:31.183Z","updated_at":"2025-02-25T14:39:57.704Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","source_id_and_acronym":"NCT03578367 - ASC4MORE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2025-02-14"},{"id":"03bbf3c8-c3f3-4829-8090-3434c8fc4bb8","acronym":"ASC4START","url":"https://clinicaltrials.gov/study/NCT05456191","created_at":"2022-07-13T12:56:30.124Z","updated_at":"2025-02-25T16:46:11.226Z","phase":"Phase 3","brief_title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","source_id_and_acronym":"NCT05456191 - ASC4START","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 574","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 07/07/2031","study_completion_date":" 07/07/2031","last_update_posted":"2025-02-06"},{"id":"1fb9a843-c4ef-444b-994a-39091f7c4fca","acronym":"ENESTop","url":"https://clinicaltrials.gov/study/NCT01698905","created_at":"2021-01-19T06:04:36.924Z","updated_at":"2025-02-25T17:35:30.294Z","phase":"Phase 2","brief_title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","source_id_and_acronym":"NCT01698905 - ENESTop","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 12/20/2012","start_date":" 12/20/2012","primary_txt":" Primary completion: 11/26/2015","primary_completion_date":" 11/26/2015","study_txt":" Completion: 01/19/2025","study_completion_date":" 01/19/2025","last_update_posted":"2025-01-29"},{"id":"8ee6a642-903b-4775-8ffb-3149fa1ecff5","acronym":"ENESTFreedom","url":"https://clinicaltrials.gov/study/NCT01784068","created_at":"2021-01-17T17:35:07.021Z","updated_at":"2025-02-25T17:35:31.954Z","phase":"Phase 2","brief_title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","source_id_and_acronym":"NCT01784068 - ENESTFreedom","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 Y253H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 Y253H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-01-29"},{"id":"de0eb004-7071-4d0b-b9a0-5aa41fe0d166","acronym":"PInNACLe","url":"https://clinicaltrials.gov/study/NCT02001818","created_at":"2021-01-18T09:08:24.888Z","updated_at":"2025-02-25T15:41:09.436Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","source_id_and_acronym":"NCT02001818 - PInNACLe","lead_sponsor":"Australasian Leukaemia and Lymphoma Group","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/11/2014","start_date":" 04/11/2014","primary_txt":" Primary completion: 01/07/2022","primary_completion_date":" 01/07/2022","study_txt":" Completion: 01/07/2022","study_completion_date":" 01/07/2022","last_update_posted":"2024-08-06"},{"id":"0d376833-0db0-4c3f-a481-a0fdb012621c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04449549","created_at":"2021-01-18T21:24:29.334Z","updated_at":"2024-07-02T16:34:25.844Z","phase":"Phase 2","brief_title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","source_id_and_acronym":"NCT04449549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2024-06-14"},{"id":"cf9f2b4a-201f-4caa-8789-84fd3a614f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554341","created_at":"2023-06-18T20:08:30.389Z","updated_at":"2024-07-02T16:34:27.622Z","phase":"Phase 2","brief_title":"Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-10"},{"id":"a27b7cf2-f99d-42a1-97ab-640fcfb897fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01746836","created_at":"2021-01-18T07:39:23.997Z","updated_at":"2024-07-02T16:34:59.088Z","phase":"Phase 2","brief_title":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","source_id_and_acronym":"NCT01746836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCR","pipe":"","alterations":" ","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • Iclusig (ponatinib) • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/17/2013","start_date":" 01/17/2013","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-06-04"},{"id":"0e780db3-37b0-4fba-8b2c-04f23ba71bda","acronym":"ASC4FIRST","url":"https://clinicaltrials.gov/study/NCT04971226","created_at":"2021-07-21T12:52:37.177Z","updated_at":"2024-07-02T16:35:06.088Z","phase":"Phase 3","brief_title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","source_id_and_acronym":"NCT04971226 - ASC4FIRST","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 01/18/2028","study_completion_date":" 01/18/2028","last_update_posted":"2024-05-03"},{"id":"4d198146-63bc-4094-95ef-0d64c81f21ec","acronym":"DANTE","url":"https://clinicaltrials.gov/study/NCT03874858","created_at":"2021-01-18T19:06:17.053Z","updated_at":"2024-07-02T16:35:08.487Z","phase":"Phase 2","brief_title":"De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination","source_id_and_acronym":"NCT03874858 - DANTE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR • TFRC","pipe":"","alterations":" ","tags":["ABL1 • BCR • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/22/2019","start_date":" 03/22/2019","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-22"},{"id":"1cd8b8e0-c288-4356-b1d4-81c289387f1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838041","created_at":"2021-04-08T12:52:35.090Z","updated_at":"2024-07-02T16:35:11.769Z","phase":"Phase 2","brief_title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","source_id_and_acronym":"NCT04838041","lead_sponsor":"Medical College of Wisconsin","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-04-03"},{"id":"58a13adb-b09f-4fe4-9e51-f50226226a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05143840","created_at":"2021-12-03T17:53:27.865Z","updated_at":"2024-07-02T16:35:12.755Z","phase":"Phase 2","brief_title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05143840","lead_sponsor":"Augusta University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-03-26"},{"id":"d266febd-e7eb-45d8-8721-ec2eb98b80b6","acronym":"CABL001X2101","url":"https://clinicaltrials.gov/study/NCT02081378","created_at":"2021-01-17T17:18:50.733Z","updated_at":"2024-07-02T16:35:14.287Z","phase":"Phase 1","brief_title":"A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL","source_id_and_acronym":"NCT02081378 - CABL001X2101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 326","initiation":"Initiation: 04/24/2014","start_date":" 04/24/2014","primary_txt":" Primary completion: 06/03/2021","primary_completion_date":" 06/03/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2024-03-18"},{"id":"a976d708-4f7e-45aa-b0eb-eedbc6a94f74","acronym":"TOKIN","url":"https://clinicaltrials.gov/study/NCT04626024","created_at":"2021-01-19T20:35:32.623Z","updated_at":"2024-07-02T16:35:26.331Z","phase":"Phase 2","brief_title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","source_id_and_acronym":"NCT04626024 - TOKIN","lead_sponsor":"Baylor College of Medicine","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2025","study_completion_date":" 11/15/2025","last_update_posted":"2023-12-13"},{"id":"ad4009b9-6655-43aa-9329-c39a4a17e94c","acronym":"NAUT","url":"https://clinicaltrials.gov/study/NCT02917720","created_at":"2022-04-24T08:57:58.867Z","updated_at":"2024-07-02T16:35:26.604Z","phase":"Phase 2","brief_title":"2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients","source_id_and_acronym":"NCT02917720 - NAUT","lead_sponsor":"European LeukemiaNet","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-12-11"},{"id":"5707c6ec-eb43-4628-b8d7-6c364ba41606","acronym":"ECOG-ACRIN EA9171","url":"https://clinicaltrials.gov/study/NCT03516279","created_at":"2021-01-18T17:18:27.696Z","updated_at":"2024-07-02T16:35:27.922Z","phase":"Phase 2","brief_title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","source_id_and_acronym":"NCT03516279 - ECOG-ACRIN EA9171","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ABL1 • BCR • CD4","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • dasatinib • imatinib • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2031","study_completion_date":" 08/31/2031","last_update_posted":"2023-11-28"},{"id":"1be42d69-4042-461f-b4f8-dc4841bc042b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654768","created_at":"2022-04-24T08:59:37.394Z","updated_at":"2024-07-02T16:35:29.499Z","phase":"Phase 2","brief_title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03654768","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • Jakafi (ruxolitinib) • nilotinib • bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-13"},{"id":"79d9e8dd-d27c-44f5-bb7c-a7b9337ae722","acronym":"HS-2020-07SZ","url":"https://clinicaltrials.gov/study/NCT04739826","created_at":"2022-04-24T09:03:01.372Z","updated_at":"2024-07-02T16:35:30.382Z","phase":"","brief_title":"Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04739826 - HS-2020-07SZ","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 491","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-03"},{"id":"124733e2-b9ad-44a7-8623-81415383bdbd","acronym":"TIKlet","url":"https://clinicaltrials.gov/study/NCT01860456","created_at":"2022-04-24T08:56:20.848Z","updated_at":"2024-07-02T16:35:34.281Z","phase":"","brief_title":"TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study","source_id_and_acronym":"NCT01860456 - TIKlet","lead_sponsor":"University of Pisa","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 412","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-09"},{"id":"d1abb299-75eb-4123-937e-3364761ded12","acronym":"NOFRETETE","url":"https://clinicaltrials.gov/study/NCT05734053","created_at":"2023-02-17T15:01:07.120Z","updated_at":"2024-07-02T16:35:39.626Z","phase":"","brief_title":"Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line","source_id_and_acronym":"NCT05734053 - NOFRETETE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Completed","enrollment":" Enrollment 222","initiation":"Initiation: 06/28/2016","start_date":" 06/28/2016","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 09/08/2022","study_completion_date":" 09/08/2022","last_update_posted":"2023-08-21"},{"id":"4893e4f0-4406-4533-aee9-63908fb17f49","acronym":"FINESTdm","url":"https://clinicaltrials.gov/study/NCT04681820","created_at":"2021-01-19T20:46:48.858Z","updated_at":"2024-07-02T16:35:41.428Z","phase":"","brief_title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","source_id_and_acronym":"NCT04681820 - FINESTdm","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-01"},{"id":"a90c12af-1488-49fd-8227-53ad777d6907","acronym":"HALF","url":"https://clinicaltrials.gov/study/NCT04147533","created_at":"2021-01-18T20:19:02.103Z","updated_at":"2024-07-02T16:35:43.839Z","phase":"Phase 2","brief_title":"Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04147533 - HALF","lead_sponsor":"Masaryk University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-07-06"},{"id":"983aaac7-64d1-4282-a35f-5f3da2b05623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01806571","created_at":"2021-01-18T08:00:32.931Z","updated_at":"2024-07-02T16:35:46.814Z","phase":"Phase 2","brief_title":"Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01806571","lead_sponsor":"Mayo Clinic","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • nilotinib • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/12/2015","start_date":" 03/12/2015","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 11/30/2019","study_completion_date":" 11/30/2019","last_update_posted":"2023-05-31"}]